RxDoctor Payments Data

Karin Sandved, MD

Internal Medicine · Norfolk, VANPI 1053321364

Payments from drug & device makers

$928in general payments, 2019–2025

Across 54 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$234
  • Amgen$144
  • Pfizer$140
  • Johnson & Johnson$87
  • Novo Nordisk$77
  • Currax Pharmaceuticals LLC$73
  • plus $174 from 7 others

What the payments were for

  • Food & beverage$928100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$928 in reported general payments places this provider in the 75th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$153,247
Medicare patients
368
Services billed
1,791

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$66,195
TrulicityDulaglutide39$62,085
JardianceEmpagliflozin46$52,867
EliquisApixaban48$47,546
JanuviaSitagliptin Phosphate51$36,200
XareltoRivaroxaban34$23,964
FarxigaDapagliflozin Propanediol17$17,052
MyrbetriqMirabegron11$13,678
Janumet XrSitagliptin Phos/Metformin Hcl12$8,010
Bupropion XlBupropion Hcl20$4,072
Rosuvastatin Calcium103$3,971
Desvenlafaxine Succinate ErDesvenlafaxine Succinate16$3,843
SymbicortBudesonide/Formoterol Fumarate11$3,744
Fentanyl29$3,683
Metoprolol Succinate189$3,392

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$77$66,19541 claims
PfizerEliquis, Paxlovid$140$48,91465 claims
MerckJanuvia, Janumet Xr$17$44,21063 claims
Johnson & JohnsonXarelto$87$23,96434 claims
AstraZenecaFarxiga, Symbicort$58$20,79628 claims
Astellas Pharma US IncMyrbetriq$23$13,67811 claims
AbbVieSynthroid$234$88133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →